NCT05716035View on ClinicalTrials.gov

Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2024

Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG

Tocilizumab Injection

Participants will receive IV tocilizumab

Trial Locations (6)

100050

NOT_YET_RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

200040

RECRUITING

Huashan Hospital, Shanghai

300052

RECRUITING

Tianjin medical university general hospital, Tianjin

410008

NOT_YET_RECRUITING

Xiangya Hospital Central South University, Changsha

610041

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu

710038

RECRUITING

Tangdu Hospital, The Fourth Military Medical University, Xi'an

All Listed Sponsors
lead

Tang-Du Hospital

OTHER